Based on the knowledge that PD-L1 expression protects tumor cells from pro-apoptotic agents [12], and that the PD-1/PD-L1 axis is correlated with negative patient outcomes [8], we postulated that the PD-1/PD-L1 axis also contributes to the acquisition of resistance to conventional chemotherapeutic agents. The gene discussed is CD274; the disease is neoplasm.